3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Neoplasms
3
Skin Diseases
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Communicable Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Autoimmune Diseases
1
Interventions
selinexor
1
pazopanib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Pregnancy Tests
1
Paclitaxel
1
Human Papillomavirus DNA Tests
1
GX-188 vaccine
1
Drug Therapy
1
Colposcopy
1
Carboplatin
1
Biopsy
1
Acetic Acid
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Diseases
×
Watchful Waiting
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled